686 related articles for article (PubMed ID: 20460912)
1. Liver fat in the pathogenesis of insulin resistance and type 2 diabetes.
Yki-Järvinen H
Dig Dis; 2010; 28(1):203-9. PubMed ID: 20460912
[TBL] [Abstract][Full Text] [Related]
2. Fatty liver: a novel component of the metabolic syndrome.
Kotronen A; Yki-Järvinen H
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):27-38. PubMed ID: 17690317
[TBL] [Abstract][Full Text] [Related]
3. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
Caldwell SH; Ikura Y; Iezzoni JC; Liu Z
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S11-9. PubMed ID: 17567458
[TBL] [Abstract][Full Text] [Related]
4. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models.
den Boer M; Voshol PJ; Kuipers F; Havekes LM; Romijn JA
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):644-9. PubMed ID: 14715643
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven GM
Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
[TBL] [Abstract][Full Text] [Related]
6. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
7. Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes.
Kotronen A; Juurinen L; Tiikkainen M; Vehkavaara S; Yki-Järvinen H
Gastroenterology; 2008 Jul; 135(1):122-30. PubMed ID: 18474251
[TBL] [Abstract][Full Text] [Related]
8. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease.
Parekh S; Anania FA
Gastroenterology; 2007 May; 132(6):2191-207. PubMed ID: 17498512
[TBL] [Abstract][Full Text] [Related]
9. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
10. Impact of non-alcoholic fatty liver disease on accelerated metabolic complications.
Fan JG
J Dig Dis; 2008 May; 9(2):63-7. PubMed ID: 18419637
[TBL] [Abstract][Full Text] [Related]
11. The metabolic syndrome and nonalcoholic fatty liver disease.
Collantes RS; Ong JP; Younossi ZM
Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
[TBL] [Abstract][Full Text] [Related]
12. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance.
Annuzzi G; Giacco R; Patti L; Di Marino L; De Natale C; Costabile G; Marra M; Santangelo C; Masella R; Rivellese AA
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):531-8. PubMed ID: 18321693
[TBL] [Abstract][Full Text] [Related]
13. Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction.
Van Gaal L
Verh K Acad Geneeskd Belg; 1989; 51(1):47-80. PubMed ID: 2800685
[TBL] [Abstract][Full Text] [Related]
14. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
15. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
16. Fat in the liver and insulin resistance.
Yki-Järvinen H
Ann Med; 2005; 37(5):347-56. PubMed ID: 16179270
[TBL] [Abstract][Full Text] [Related]
17. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
[TBL] [Abstract][Full Text] [Related]
18. [Non-alcoholic fatty liver disease in dyslipidemia and insulin resistance: similarities and differences; differential approach to therapy].
Lazebnik LB; Zvenigorodskaia LA; Egorova EG; Mel'nikova NV; Khomeriki SG
Eksp Klin Gastroenterol; 2009; (8):4-11. PubMed ID: 20469672
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
Watts GF; Ooi EM; Chan DC
Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
Marchesini G; Bugianesi E; Forlani G; Cerrelli F; Lenzi M; Manini R; Natale S; Vanni E; Villanova N; Melchionda N; Rizzetto M
Hepatology; 2003 Apr; 37(4):917-23. PubMed ID: 12668987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
